Recordati posts solid H1 2026 growth with revenue up 6.6% and EBITDA up 8.8%
Executive summary: Recordati reported H1 2026 net revenue of +6.6%, EBITDA +8.8% and adjusted net income +6.7% versus the same period in 2025. The performance signals sustained organic growth and profitability, reinforcing investor confidence in the group’s pipeline and commercial execution.
Who is involved: Recordati S.p.A., its Board of Directors, and shareholders; the results were disclosed via a GlobeNewswire press release.
Likely next: Analysts will watch for Q3 2026 trading updates and any revision to full‑year guidance later in the year.
Recordati S.p.A. announced first‑half 2026 results showing net revenue rose 6.6% year‑on‑year, EBITDA increased 8.8% and adjusted net income grew 6.7%. The figures reflect continued momentum across the group’s pharmaceutical portfolio, driven by higher sales of specialty and rare‑disease medicines. The release underscores the company’s ability to deliver profit growth despite a challenging macro‑environment.
Timeline
- — RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7% (GlobeNewswire)
Key entities
Sources
Open the full interactive case file on Beyond →